Akari Therapeutics
AKTX
14 hedge funds and large institutions have $14.5M invested in Akari Therapeutics in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
27% more funds holding
Funds holding: 11 → 14 (+3)
0.45% less ownership
Funds ownership: 7.09% → 6.64% (-0.45%)
61% less capital invested
Capital invested by funds: $37M → $14.5M (-$22.5M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.12M |
| 2 |
HP
Hikari Power
Tokyo,
Japan
|
+$593K |
| 3 |
VMI
VHCP Management II
New York
|
+$561K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$127K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$71.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$3.28M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$1.05M |
| 3 |
QF
QVT Financial
New York
|
-$759K |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$516K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$214K |
AKTX Hedge Fund Activity: Q2 2017 in Review
14 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2017, worth a combined $14.5M — down 61% from $37M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AKTX positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.12M. The largest seller was Deerfield Management, cutting an estimated $3.28M.
- 14 institutional investors held Akari Therapeutics (AKTX) as of Q2 2017, up from 11 in Q1 2017.
- Funds reported $14.5M of Akari Therapeutics stock for Q2 2017, down 61% quarter-over-quarter.
- 6 funds opened new Akari Therapeutics positions in Q2 2017 and 3 closed out, a net change of +3 holders.
- The largest Akari Therapeutics buyer in Q2 2017 was Millennium Management, an estimated $2.12M added.
- The largest Akari Therapeutics seller in Q2 2017 was Deerfield Management, an estimated $3.28M sold.
Based on aggregated 13F filings for Q2 2017.